Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 2/2016

16.02.2016 | Review Article

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

verfasst von: Aditi Bhatt, Olivier Glehen

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.
Literatur
1.
Primary Cytoreductive Surgery for Advanced Stage Ovarian Cancer: indications for Radical Resection; Bristow R. Cancerología 2; Suplemento 1 (2007): s31-s36
2.
Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L (2009) Gülten O; Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99(7):424–427CrossRefPubMed
3.
4.
Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O (2014) Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 151:347–353CrossRefPubMed
5.
Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed
6.
Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974–979CrossRefPubMed
7.
Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159–166CrossRefPubMed
8.
Whitney CW, Spirtos N (2009) Gynecologic oncology group surgical procedures manual. Philadelphia Gynecologic Oncology Group
9.
Chi DS, Ramirez PT, Teitcher JB, et al. (2007) Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol 25:4946–4951CrossRefPubMed
10.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRefPubMed
11.
Aletti GD, Dowdy SC, Podratz KC, Cliby WA (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100:283–287CrossRefPubMed
12.
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103:1083–1090CrossRefPubMed
13.
Eisenkop SM, Spirtos NM, Friedman RL, et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol 90:390–396CrossRefPubMed
14.
Chi DS, Eisenhauer EL, Zivanovic O, et al. (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31CrossRefPubMed
15.
Bukowski RM, Ozols RF, Markman M (2007) The management of recurrent ovarian cancer. Semin Oncol 34:S1–15CrossRefPubMed
16.
Makara AR, Coleman RL (2004) Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95:273–280CrossRef
17.
Schorge J, McCann C, Del Carmen M (2010) Surgical Debulking of Ovarian Cancer: What Difference Does It Make? Rev Obstet Gynecol 3(3):111–117PubMedPubMedCentral
18.
Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265–274CrossRefPubMed
19.
Fotiou S, Aliki T, Petros Z, et al. (2009) Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol 114:178–182CrossRefPubMed
20.
Schorge JO, Wingo SN, Bhore R, et al. (2010) Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet 108:123–127CrossRefPubMed
21.
Harter P, du Bois A, Hahmann M, et al. (2006) Surgery in recur-rent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710CrossRefPubMed
22.
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295CrossRefPubMed
23.
Cotte E, Colomban O, Guitton J, et al. (2011) Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol 51(1):9–18CrossRefPubMed
24.
Alberts DS, Liu PY, Hannigan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955CrossRefPubMed
25.
Markman M, Bundy BN, Alberts DS, et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 19:1001–1007PubMed
26.
Armstrong DK, Bundy B, Wenzel L, et al. (2006) Intraperitoneal cisplatin and paclitaxel in Ovarian cancer. N Engl J Med 354:34–43CrossRefPubMed
27.
Elit L, Oliver TK, Covens A, Kwon J, Fung MK, Hirte HW, Oza AM (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta- analysis. Cancer 109:692–702CrossRefPubMed
28.
Glehen O, Gilly FN (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemo hyperthermia. Lancet Oncol 5:219–228CrossRefPubMed
29.
Hettinga JV, Konings AW, Kampinga HH (1997) Reduction of cellular cisplatin resistance by hyperthermia — a review. Int J Hyperth 13:439–457CrossRef
30.
van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34(1):148–154CrossRefPubMed
31.
Chua TC, Moran BJ, Sugarbaker PH, et al. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456CrossRefPubMed
32.
Yan TD, Deraco M, Baratti D, et al. (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242CrossRefPubMed
33.
Elias D, Gilly F, Boutitie F, et al. (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68CrossRefPubMed
34.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432CrossRefPubMed
35.
Glehen O, Gilly FN, Arvieux C, et al. (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRefPubMed
36.
Glehen O, Passot G, Villeneuve L, et al. (2014) GASTRICHIP: D2resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multi-center phase III study. BMC Cancer 14:183CrossRefPubMedPubMedCentral
37.
Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F (2012) Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence. Curr Pharm Des 18:3793–3803CrossRefPubMed
38.
39.
Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:21CrossRefPubMedPubMedCentral
40.
Yoshida Y, Sasaki H, Kurokawa T, et al. (2005) Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up. Oncol Rep 13(1):121–125PubMed
41.
Rufián S, Muñoz-Casares FC, Briceño J, et al. (2006) Radical surgery peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316–324CrossRefPubMed
42.
Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM (2009) Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer - 12-year single center experience. Eur J Surg Oncol 35(11):1186–1191CrossRefPubMed
43.
Pomel C, Ferron G, Lorimier G, et al. (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36(6):589–593CrossRefPubMed
44.
Roviello F, Pinto E, Corso G, et al. (2010) Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol 102(6):663–670CrossRefPubMed
45.
Parson EN, Lentz S, Russell G, et al. (2011) Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg 202(4):481–486CrossRefPubMed
46.
Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, et al. (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol 39:1109–1115CrossRefPubMed
47.
Helm CW, Richard SD, Pan J, et al. (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20(1):61–69CrossRefPubMed
48.
Deraco M, Kusamura S, Virzì S, et al. (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 122(2):215–220CrossRefPubMed
49.
Bakrin N, Bereder JM, Decullier E, et al. (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of566 patients. Eur J Surg Oncol 39:1435–1443CrossRefPubMed
50.
Gori J, Castaño R, Toziano M, et al. (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15:233–239CrossRefPubMed
51.
Vergote I, Tropé CG, Amant F, et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953CrossRefPubMed
52.
Kumar L, Hariprasad R, Kumar S, et al. (2010) Upfront surgery vs neoadjuvant, chemotherapy in advanced epithelial ovarian carcinoma (EOC): a randomized, study. IGCS 13. Prague (A824)
53.
Chi DS, Musa F, Dao F, et al. (2011) An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124(1):10–14CrossRefPubMed
54.
Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C (2010) Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer 20(8):1331–1340PubMed
55.
Morice P, Brehier-Ollive D, Rey A, et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-nonexposed study. Ann Oncol 14(1):74–77CrossRefPubMed
56.
Onda T, Kobayashi H, Nakanishi T, et al. (2009) Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol 113(1):57–62CrossRefPubMed
57.
Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS (2006) Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 32(1):99–10CrossRefPubMed
58.
van der Vange N, van Goethem AR, Zoetmulder FAN, et al. (2000) Extensive cytoreductive surgery combined with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 26:663–668CrossRefPubMed
59.
Zanon C, Clara R, Chiappino I, et al. (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040–1045CrossRefPubMed
60.
Cotte E, Glehen O, Mohamed F, et al. (2007) Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31:1813–1820CrossRefPubMed
61.
Di Giorgio A, Naticchioni E, Biacchi D, et al. (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113(2):315–325CrossRefPubMed
62.
Carrabin N, Mithieux F, Meeus P, et al. (2010) Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer 97(4):E23–E32PubMed
63.
Königsrainer I, Beckert S, Becker S, et al. (2011) Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbeck's Arch Surg 396(7):1077–1081CrossRef
64.
Frenel JS, Leux C, Pouplin L, et al. (2011) Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. J Surg Oncol 103(1):10–16CrossRefPubMed
65.
Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P (2009) Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 19(7):2352–2359
66.
Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 1:54–61. doi:10.​3802/​jgo.​2015.​26.​1.​54 CrossRef
67.
Munoz-Casares FC, Rufian S, Rubio MJ, et al. (2009) The role of hyper-thermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 11:753–759CrossRefPubMed
68.
Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A (2011) The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 16:74–79PubMed
69.
Fagotti A, Costantini B, Petrillo M, et al. (2012) Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-up. Gynecol Oncol 127:502–505CrossRefPubMed
70.
Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM (2014) Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improvesprogression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol 110(6):661–665. doi:10.​1002/​jso.​23688 CrossRefPubMed
71.
Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ (2015) Parrilla The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrentepithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 22(3):987–993. doi:10.​1245/​s10434-014-4049-z CrossRefPubMed
72.
Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94(11):1408–1414CrossRefPubMed
73.
Raspagliesi F, Kusamura S, Campos Torres JC, et al. (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32:671–675CrossRefPubMed
74.
Kim JH, Lee JM, Ryu KS, et al. (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101(2):149–155PubMed
75.
Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907CrossRefPubMed
76.
Glehen O, Gilly FN, Boutitie F, et al. (2010) Toward curative treatment of peritoneal carcinomatosis from non- ovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116:5608–5618CrossRefPubMed
77.
Elias DM, Ouellet JF (2001) Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am 10:915–933PubMed
78.
Hettinga JV, Lemstra W, Meijer C, Dam WA, Uges DR, Konings AW, De Vries EG, Kampinga HH (1997) Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells. Br J Cancer 75:1735–1743CrossRefPubMedPubMedCentral
Metadaten
Titel
The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review
verfasst von
Aditi Bhatt
Olivier Glehen
Publikationsdatum
16.02.2016
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2016
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-016-0501-9

Weitere Artikel der Ausgabe 2/2016

Indian Journal of Surgical Oncology 2/2016 Zur Ausgabe

Review Article

Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei

Review Article

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours

Review Article

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Preface

Preface

Review Article

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Review Article

Cytoreductive Surgery and Peritonectomy Procedures

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.